DAIICHI-SANKYO
27.5.2024 09:01:28 CEST | Business Wire | Press release
Daiichi Sankyo Europe (hereafter, Daiichi Sankyo) today announced the launch of the Future of Heart Health in Europe: A Holistic Care Think Tank report. The report follows the first-of-its-kind holistic care Think Tank meeting, held earlier this year, which brought together influential representatives from various disciplines including clinicians, patient advocates, researchers, digital and media experts and policy specialists. Three strategic recommendations for incorporating a holistic approach to CV care in Europe arose from the meeting:
-
Improve lifelong support and education:
- Improving lifelong support and education from a young age to lay a strong foundation for sustained wellness; introducing programmes in the workplace that reward physical and mental well-being.
-
Increase interdisciplinary collaboration and communication:
- Assigning a patient case manager and embracing implementation of artificial intelligence to improve communication and coordination of interdisciplinary collaboration.
-
Changes in health policies across Europe:
- A holistic view of CV care should be included on political agendas at a European level. Policy changes will lead to better access to preventative care, support for the adoption of a healthy lifestyle, and removal of barriers to equitable healthcare.
Across Europe, CVD is responsible for the loss of 10,000 lives every day.3 However, cardiovascular conditions are largely preventable, and there is a growing emphasis on addressing the burden of CVD through behavioural changes and risk factor management. The holistic care Think Tank included experts with a focus on behavioural and physiological factors for CVD, such as diet, exercise, and mental health. These experts play a vital role in raising awareness of the various aspects of CVD and, together, can build a more holistic picture of a person’s health that goes beyond the view of the heart alone.
"Collaborating with a diverse array of stakeholders is paramount in adopting a truly holistic approach to heart health in Europe,” said Berk Kiran, Vice President, Commercial Operations Europe, Daiichi Sankyo Europe. “By harnessing the unique perspectives and expertise of individuals across disciplines, sectors, and backgrounds, we can help forge innovative solutions that address the challenges facing cardiovascular health today. Together, we can drive meaningful change and pave the way towards a healthier future for all."
“At a political level, I think that it's time to establish health promotion and cardiovascular prevention as a real priority,” said Professor Hélder Dores, Cardiologist, Portugal and member of the Think Tank. “In healthcare, I think that not only for cardiologists but for all the professionals, it’s important to amend how we’re determining an individual’s risk and to improve lifestyle, because as we know, the great majority of atherosclerotic events could be prevented if we address the underlying risk factors.”
The inaugural Think Tank meeting and report form part of Daiichi Sankyo’s ongoing heart health initiative: We Care for Every Heartbeat (WC4EHB).
For further information on holistic approaches to CV health and care in Europe and to read the full report please visit our WC4EHB website: https://wecareforeveryheartbeat.com/.
-ENDS-
About We Care for Every Heartbeat
At Daiichi Sankyo we care for every heartbeat. Our goal is to protect people from cardiovascular disease and help those who suffer from it, so they can enjoy every precious moment that life has to offer. Under the WC4EHB umbrella, Daiichi Sankyo regularly publishes informational blogs designed to improve health literacy and CVD care across Europe. We have conducted awareness surveys to uncover the public perception and attitude towards heart disease. We are working with external organisations, such as The Economist and the European Nutrition for Health Alliance (ENHA), to better understand the burden of CVD in Europe, and we partner with health specialists across a range of CV-relevant professions to advocate for greater collaboration and a holistic approach in Europe. We have made a long-term commitment to invest and work tirelessly to help patients and inspire positive change in CV care. For further information on WC4EHB and our activities, visit our website: https://wecareforeveryheartbeat.com/.
About CVD in Europe
CVD – a group of disorders affecting the heart and circulatory system, which can lead to heart attacks and strokes – is the primary cause of death in Europe, accounting for 45% of all deaths in the region and responsible for more than 10,000 lives lost every day.3,4,5,6 Furthermore, a large proportion of these deaths are premature – occurring before the age of 65 years – with CVD responsible for almost a quarter of premature deaths among men and nearly a fifth among women in Europe.7 Despite its high prevalence and burden, a lack of public awareness and gaps in understanding, especially of CVD risk factors, may be preventing those at risk from making positive lifestyle changes and adopting healthy habits to help reduce their CVD risk.8
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need.
For more information, please visit www.daiichisankyo.com
| References |
_____________________________ |
1 World Health Organization. Cardiovascular Diseases (CVDs) Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Last accessed May 2024. |
2 Luengo-Fernandez, R., et al. Economic burden of cardiovascular diseases in the European Union: a population-based cost study. Eur Heart J. 2023. 00: 1–16. |
3 Mach, F., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020. 41;(1): 111–188. |
4 European Heart Network. European Cardiovascular Disease Statistics 2017 edition. Available at: https://ehnheart.org/wp-content/uploads/2023/07/CVD-Statistics.pdf. Last accessed May 2024. |
5 European Heart Network. CVD Statistics. Available at: https://ehnheart.org/about-cvd/the-burden-of-cvd/. Last accessed May 2024. |
6 Eurostat. Causes of death statistics. Available at: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Causes_of_death_statistics#Major_causes_of_death_in_the_EU_in_2020. Last accessed May 2024. |
7 European Heart Network. Fighting cardiovascular disease – a blueprint for EU action. Available at: https://www.escardio.org/static-file/Escardio/Advocacy/Documents/2020%20ESC-EHN-blueprint_digital%20edition.pdf. Last accessed May 2024. |
8 Daiichi Sankyo We Care for Every Heartbeat. European Survey Report of Cardiovascular Disease – Uncovering current public perceptions and attitudes towards cardiovascular disease. Available at: wecareforeveryheartbeat.com/wp-content/uploads/2023/08/European_Survey_Report_final_approved_Jul_2022.pdf. Last accessed May 2024. |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240520608896/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
